172 related articles for article (PubMed ID: 32029440)
1. c-Src Phosphorylates and Inhibits the Function of the CIC Tumor Suppressor Protein.
Bunda S; Heir P; Li ASC; Mamatjan Y; Zadeh G; Aldape K
Mol Cancer Res; 2020 May; 18(5):774-786. PubMed ID: 32029440
[TBL] [Abstract][Full Text] [Related]
2. CIC protein instability contributes to tumorigenesis in glioblastoma.
Bunda S; Heir P; Metcalf J; Li ASC; Agnihotri S; Pusch S; Yasin M; Li M; Burrell K; Mansouri S; Singh O; Wilson M; Alamsahebpour A; Nejad R; Choi B; Kim D; von Deimling A; Zadeh G; Aldape K
Nat Commun; 2019 Feb; 10(1):661. PubMed ID: 30737375
[TBL] [Abstract][Full Text] [Related]
3. YAP/TAZ Transcriptional Coactivators Create Therapeutic Vulnerability to Verteporfin in EGFR-mutant Glioblastoma.
Vigneswaran K; Boyd NH; Oh SY; Lallani S; Boucher A; Neill SG; Olson JJ; Read RD
Clin Cancer Res; 2021 Mar; 27(5):1553-1569. PubMed ID: 33172899
[TBL] [Abstract][Full Text] [Related]
4. EGFR Activates a TAZ-Driven Oncogenic Program in Glioblastoma.
Gao M; Fu Y; Zhou W; Gui G; Lal B; Li Y; Xia S; Ji H; Eberhart CG; Laterra J; Ying M
Cancer Res; 2021 Jul; 81(13):3580-3592. PubMed ID: 33910930
[TBL] [Abstract][Full Text] [Related]
5. Constitutive CHK1 Expression Drives a pSTAT3-CIP2A Circuit that Promotes Glioblastoma Cell Survival and Growth.
Khanna A; Thoms JAI; Stringer BW; Chung SA; Ensbey KS; Jue TR; Jahan Z; Subramanian S; Anande G; Shen H; Unnikrishnan A; McDonald KL; Day BW; Pimanda JE
Mol Cancer Res; 2020 May; 18(5):709-722. PubMed ID: 32079743
[TBL] [Abstract][Full Text] [Related]
6. A molecular cascade modulates MAP1B and confers resistance to mTOR inhibition in human glioblastoma.
Laks DR; Oses-Prieto JA; Alvarado AG; Nakashima J; Chand S; Azzam DB; Gholkar AA; Sperry J; Ludwig K; Condro MC; Nazarian S; Cardenas A; Shih MYS; Damoiseaux R; France B; Orozco N; Visnyei K; Crisman TJ; Gao F; Torres JZ; Coppola G; Burlingame AL; Kornblum HI
Neuro Oncol; 2018 May; 20(6):764-775. PubMed ID: 29136244
[TBL] [Abstract][Full Text] [Related]
7. A Preclinical Investigation of GBM-N019 as a Potential Inhibitor of Glioblastoma via Exosomal mTOR/CDK6/STAT3 Signaling.
Wu ATH; Huang HS; Wen YT; Lawal B; Mokgautsi N; Huynh TT; Hsiao M; Wei L
Cells; 2021 Sep; 10(9):. PubMed ID: 34572040
[TBL] [Abstract][Full Text] [Related]
8. REST-DRD2 mechanism impacts glioblastoma stem cell-mediated tumorigenesis.
Marisetty AL; Lu L; Veo BL; Liu B; Coarfa C; Kamal MM; Kassem DH; Irshad K; Lu Y; Gumin J; Henry V; Paulucci-Holthauzen A; Rao G; Baladandayuthapani V; Lang FF; Fuller GN; Majumder S
Neuro Oncol; 2019 Jun; 21(6):775-785. PubMed ID: 30953587
[TBL] [Abstract][Full Text] [Related]
9. RND2 attenuates apoptosis and autophagy in glioblastoma cells by targeting the p38 MAPK signalling pathway.
Xu Y; Sun Q; Yuan F; Dong H; Zhang H; Geng R; Qi Y; Xiong X; Chen Q; Liu B
J Exp Clin Cancer Res; 2020 Aug; 39(1):174. PubMed ID: 32867814
[TBL] [Abstract][Full Text] [Related]
10. PKCδ activated by c-MET enhances infiltration of human glioblastoma cells through NOTCH2 signaling.
Hwang E; Yoo KC; Kang SG; Kim RK; Cui YH; Lee HJ; Kim MJ; Lee JS; Kim IG; Suh Y; Lee SJ
Oncotarget; 2016 Jan; 7(4):4890-902. PubMed ID: 26700818
[TBL] [Abstract][Full Text] [Related]
11. ERK phosphorylation disrupts the intramolecular interaction of capicua to promote cytoplasmic translocation of capicua and tumor growth.
Park J; Park GY; Lee J; Park J; Kim S; Kim E; Park SY; Yoon JH; Lee Y
Front Mol Biosci; 2022; 9():1030725. PubMed ID: 36619173
[TBL] [Abstract][Full Text] [Related]
12. BCL6 promotes glioma and serves as a therapeutic target.
Xu L; Chen Y; Dutra-Clarke M; Mayakonda A; Hazawa M; Savinoff SE; Doan N; Said JW; Yong WH; Watkins A; Yang H; Ding LW; Jiang YY; Tyner JW; Ching J; Kovalik JP; Madan V; Chan SL; Müschen M; Breunig JJ; Lin DC; Koeffler HP
Proc Natl Acad Sci U S A; 2017 Apr; 114(15):3981-3986. PubMed ID: 28356518
[TBL] [Abstract][Full Text] [Related]
13. CD90 Expression Controls Migration and Predicts Dasatinib Response in Glioblastoma.
Avril T; Etcheverry A; Pineau R; Obacz J; Jegou G; Jouan F; Le Reste PJ; Hatami M; Colen RR; Carlson BL; Decker PA; Sarkaria JN; Vauléon E; Chiforeanu DC; Clavreul A; Mosser J; Chevet E; Quillien V
Clin Cancer Res; 2017 Dec; 23(23):7360-7374. PubMed ID: 28939749
[No Abstract] [Full Text] [Related]
14. Inhibition of cell growth and up-regulation of MAD2 in human oesophageal squamous cell carcinoma after treatment with the Src/Abl inhibitor dasatinib.
Wang L; Guo B; Wang R; Jiang Y; Qin S; Liang S; Zhao Y; Guo W; Li K; Fan X
Clin Sci (Lond); 2012 Jan; 122(1):13-24. PubMed ID: 21751967
[TBL] [Abstract][Full Text] [Related]
15. A combination of tyrosine kinase inhibitors, crizotinib and dasatinib for the treatment of glioblastoma multiforme.
Nehoff H; Parayath NN; McConnell MJ; Taurin S; Greish K
Oncotarget; 2015 Nov; 6(35):37948-64. PubMed ID: 26517812
[TBL] [Abstract][Full Text] [Related]
16. Minibrain and Wings apart control organ growth and tissue patterning through down-regulation of Capicua.
Yang L; Paul S; Trieu KG; Dent LG; Froldi F; Forés M; Webster K; Siegfried KR; Kondo S; Harvey K; Cheng L; Jiménez G; Shvartsman SY; Veraksa A
Proc Natl Acad Sci U S A; 2016 Sep; 113(38):10583-8. PubMed ID: 27601662
[TBL] [Abstract][Full Text] [Related]
17. Discovery of LAMP-2A as potential biomarkers for glioblastoma development by modulating apoptosis through N-CoR degradation.
Wang Y; Zhang B; Wang J; Wu H; Xu S; Zhang J; Wang L
Cell Commun Signal; 2021 Mar; 19(1):40. PubMed ID: 33761934
[TBL] [Abstract][Full Text] [Related]
18. Drak/STK17A Drives Neoplastic Glial Proliferation through Modulation of MRLC Signaling.
Chen AS; Wardwell-Ozgo J; Shah NN; Wright D; Appin CL; Vigneswaran K; Brat DJ; Kornblum HI; Read RD
Cancer Res; 2019 Mar; 79(6):1085-1097. PubMed ID: 30530503
[TBL] [Abstract][Full Text] [Related]
19. Src family kinases differentially influence glioma growth and motility.
Lewis-Tuffin LJ; Feathers R; Hari P; Durand N; Li Z; Rodriguez FJ; Bakken K; Carlson B; Schroeder M; Sarkaria JN; Anastasiadis PZ
Mol Oncol; 2015 Nov; 9(9):1783-98. PubMed ID: 26105207
[TBL] [Abstract][Full Text] [Related]
20. Src and STAT3 inhibitors synergize to promote tumor inhibition in renal cell carcinoma.
Lue HW; Cole B; Rao SA; Podolak J; Van Gaest A; King C; Eide CA; Wilmot B; Xue C; Spellman PT; Heiser LM; Tyner JW; Thomas GV
Oncotarget; 2015 Dec; 6(42):44675-87. PubMed ID: 26625308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
